Doxorubicin-vincristine therapy for Wilms' tumor: A pilot study

B. Camitta; L. Kun; M. Glicklich; H. Oechler; S. Adair; D. Pinkel

Doxorubicin-vincristine therapy for Wilms' tumor: A pilot study

B. Camitta, L. Kun, M. Glicklich, H. Oechler, S. Adair, D. Pinkel

Research output: Contribution to journal › Article › peer-review

Abstract

Doxorubicin plus vincristine chemotherapy was given for 31 children following nephrectomy for Wilms' tumor. Radiation therapy was used as indicated. Disease-free survival by stage is: eight of nine patients (stage I), eight of nine (stage II), nine of ten (stage III), and two of three (stage IV). Median follow-up of survivors is 28 months (range, 2-67); for all but four patients, follow-up is > 12 months. Two of the three stage I-III failures occurred in children with unfavorable histologies; the third failure was due to fatal anthracycline cardiomyopathy. Lowering the maximal cumulative doxorubicin dose from 450 to 240 mg/m² did not increase failures. Doxorubicin-vincristine appears to be effective chemotherapy for Wilms' tumor.

Original language	English (US)
Pages (from-to)	1791-1794
Number of pages	4
Journal	Cancer treatment reports
Volume	66
Issue number	10
State	Published - 1982

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{292e5a501a4e4c7e95a1da4a5907c749,

title = "Doxorubicin-vincristine therapy for Wilms' tumor: A pilot study",

abstract = "Doxorubicin plus vincristine chemotherapy was given for 31 children following nephrectomy for Wilms' tumor. Radiation therapy was used as indicated. Disease-free survival by stage is: eight of nine patients (stage I), eight of nine (stage II), nine of ten (stage III), and two of three (stage IV). Median follow-up of survivors is 28 months (range, 2-67); for all but four patients, follow-up is > 12 months. Two of the three stage I-III failures occurred in children with unfavorable histologies; the third failure was due to fatal anthracycline cardiomyopathy. Lowering the maximal cumulative doxorubicin dose from 450 to 240 mg/m2 did not increase failures. Doxorubicin-vincristine appears to be effective chemotherapy for Wilms' tumor.",

author = "B. Camitta and L. Kun and M. Glicklich and H. Oechler and S. Adair and D. Pinkel",

year = "1982",

language = "English (US)",

volume = "66",

pages = "1791--1794",

journal = "Cancer treatment reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Doxorubicin-vincristine therapy for Wilms' tumor

T2 - A pilot study

AU - Camitta, B.

AU - Kun, L.

AU - Glicklich, M.

AU - Oechler, H.

AU - Adair, S.

AU - Pinkel, D.

PY - 1982

Y1 - 1982

N2 - Doxorubicin plus vincristine chemotherapy was given for 31 children following nephrectomy for Wilms' tumor. Radiation therapy was used as indicated. Disease-free survival by stage is: eight of nine patients (stage I), eight of nine (stage II), nine of ten (stage III), and two of three (stage IV). Median follow-up of survivors is 28 months (range, 2-67); for all but four patients, follow-up is > 12 months. Two of the three stage I-III failures occurred in children with unfavorable histologies; the third failure was due to fatal anthracycline cardiomyopathy. Lowering the maximal cumulative doxorubicin dose from 450 to 240 mg/m2 did not increase failures. Doxorubicin-vincristine appears to be effective chemotherapy for Wilms' tumor.

AB - Doxorubicin plus vincristine chemotherapy was given for 31 children following nephrectomy for Wilms' tumor. Radiation therapy was used as indicated. Disease-free survival by stage is: eight of nine patients (stage I), eight of nine (stage II), nine of ten (stage III), and two of three (stage IV). Median follow-up of survivors is 28 months (range, 2-67); for all but four patients, follow-up is > 12 months. Two of the three stage I-III failures occurred in children with unfavorable histologies; the third failure was due to fatal anthracycline cardiomyopathy. Lowering the maximal cumulative doxorubicin dose from 450 to 240 mg/m2 did not increase failures. Doxorubicin-vincristine appears to be effective chemotherapy for Wilms' tumor.

UR - http://www.scopus.com/inward/record.url?scp=0019931825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019931825&partnerID=8YFLogxK

M3 - Article

C2 - 6290049

AN - SCOPUS:0019931825

SN - 0361-5960

VL - 66

SP - 1791

EP - 1794

JO - Cancer treatment reports

JF - Cancer treatment reports

IS - 10

ER -

Doxorubicin-vincristine therapy for Wilms' tumor: A pilot study

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this